Covid-19 Vaccine Acceptance and Determinant Factors among General Public in East Africa: A Systematic Review and Meta-Analysis

Astawus Alemayehu1,2, Abebaw Demissie2,4, Mohammed Yusuf2,3, Abebe Gemechu Lencha5, and Lemessa Oljira6

Abstract

Background: Vaccines are an effective and ideal solution that can reduce the burden of disease worldwide. Although vaccines are the most effective way to prevent infectious diseases. Anti-vaccine conspiracy theories impair vaccination acceptance intentions. Several studies were conducted in East Africa. However, these studies had reported inconsistent findings. Therefore, this systematic review aimed to pool the prevalence of COVID-19 vaccine acceptance and identify its determinants.

Methods: PubMed, Google Scholar, and GLOBAL HEALTH databases were used to retrieve previously published studies. All papers published in the English language up to February 28, 2022 were included. The result was written and reported according to the PRISMA updated guideline. A random-effect model was used to estimate the pooled prevalence and effect sizes. Heterogeneity was assessed using I² test statistics. Publication bias was assessed using funnel plot and eggert’s test statistics. Statistical tests result at $P$-value<0.05 were declared as having significance.

Result: A total of 25 Cross-sectional studies with a total sample size of 33,044 were included in this study. The pooled prevalence of Covid-19 vaccine acceptance was 60.2%, (95%CI: 52.8- 67.3). Eggert’s test statistics ($P = 0.003$) showed there is a significant publication bias. Attending above secondary school (AOR: 2.1, 95%CI: 1.37, 2.96), having good knowledge about the vaccine (AOR: 2.1, 95%CI: 1.6, 2.8), having a positive attitude towards vaccine (AOR: 3.8, 95%CI: 2.3, 6.2), history of COVID-19 infection (AOR: 2.7, 95%CI: 1.6, 4.7) and being male (AOR: 1.8, 95%CI: 1.2, 2.7) were found to have a significant association with COVID-19 vaccine acceptance.

Conclusion: The COVID-19 vaccination acceptance rate was good, but it could be improved. The findings could help governments to figure out the best way to carry out COVID-19 mass vaccination campaigns. There is a lack of data in most countries. Therefore, we suggest more studies be conducted in the future.

Keywords
COVID-19 vaccine, vaccine acceptance, vaccine acceptance determinants

Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic that destabilized the health, economy, and movement of individuals worldwide.1 The first COVID-19 cases were detected in Wuhan, China and the World Health Organization (WHO) declared the disease as a pandemic and public health emergency.2 Since its emergence, COVID-19 infected millions of people and has claimed millions of lives worldwide. In Africa, there have been more than 5 million confirmed cases, and more than 100 thousand deaths. In Ethiopia, there have been more than 300 thousand confirmed cases with 4711 deaths.3,4
quarantine, and nationwide lockdown.\textsuperscript{5,6} Despite the widespread use of COVID-19 prevention measures, the pandemic’s impact has not been considerably decreased. The only way out of this epidemic appears to be a large-scale COVID-19 immunization program over the world. Vaccines are an effective and excellent solution for reducing the high burden of disease around the world, including disease prevention, disease severity and death reduction, and the effects of a pandemic on a country’s health system and economy.\textsuperscript{7,8}

Although vaccines are the most effective way to prevent infectious diseases and its consequence, but their safety and efficacy have long been the subject of conspiracy theories, and this Anti-vaccine conspiracy beliefs impair vaccination acceptance intentions. Vaccine anxiety might be exacerbated by rumors and conspiracy theories.\textsuperscript{9-11} Negative claims about vaccine effectiveness historically influenced vaccine uptake. Immunization efforts have been rumored to be utilized for political goals, and such suspicions have harmed vaccination initiatives in various nations.\textsuperscript{12} The most frequently repeated rumor is that the COVID-19 vaccination may cause cancer and infertility by altering people’s Deoxyribonucleic acid (DNA), some sources, the COVID-19 vaccination was designed to reduce the global population.\textsuperscript{13} This could have an impact on vaccine policy implementation.\textsuperscript{12}

Several studies have been conducted in East Africa to identify the level and determinants for acceptance of covid-19 vaccinations however, these studies had reported inconsistent findings, regarding the level of COVID-19 acceptance rate and determinants. Some of these studies revealed an acceptance rate of greater than 50%,\textsuperscript{14-30} while others reported less than 50%.\textsuperscript{31-37} In addition, some of these studies had also shown that being male,\textsuperscript{17,20,22,26,33,34,36} and increasing in age,\textsuperscript{14,19-21,26,38} were found to have an association with COVID-19 vaccine acceptance. On the other hand, other studies have reported being female,\textsuperscript{14,15,19,32} and decreasing in age,\textsuperscript{14,15,19,20,32,38} were found to have an association with COVID-19 vaccine acceptance.

Moreover, different studies conducted in East Africa had found that attending above secondary school,\textsuperscript{14,15,20,22,25,26,29,32,34,36,38} having knowledge about COVID-19 vaccine,\textsuperscript{14,16,17,22,25,29,36,38} having a positive attitude towards COVID-19 vaccine,\textsuperscript{14,17,25,31,37} previously infected with COVID-19,\textsuperscript{14,17,21,31,34} and living in urban areas,\textsuperscript{20,25,29,32,38} were found to have different levels of

\textbf{Figure 1.} Prisma flow chart shows study selection for systematic review and meta-analysis of COVID-19 Vaccine acceptance and determinants among general population in East Africa, 2022.
| Author, year         | Country       | Study setting | Sample size | COVID-19 Vaccine acceptance (%) | Associated factors reported (OR; 95% CI)                                                                 | Quality Score (%) |
|----------------------|---------------|---------------|-------------|---------------------------------|--------------------------------------------------------------------------------------------------------|------------------|
| Abebe, Shitu et al 2021 | Ethiopia     | Population    | 492         | 62.6                            | Attending above 20 school (2.59; 1.52, 4.39) Increasing in age (> 40 years) (2.36; 1.1, 5.4) Living in Urban (1.32; 0.81, 2.17) Knowledge about COVID-19 Vaccine (2.59; 1.67, 4.02) | 88.8%            |
| Admasu 2021          | Ethiopia      | Patients      | 422         | 54.5                            | Attending above 20 school (3.01; 1.48, 6.89) Increasing in age (> 40 years) (1.13; 0.33, 3.91) Knowledge about COVID-19 Vaccine (6.9; 3.1, 15.2) Positive attitude towards COVID-19 Vaccine (3.05; 1.03, 4.05) Previously infected by COVID-19 (6; 2.5, 11.8) | 87.5%            |
| Aemro, Amare et al 2021 | Ethiopia    | Health worker | 418         | 54.1                            | Attending above 20 school (1.2; 0.7, 2.3) Knowledge about COVID-19 Vaccine (1.31; 1.23, 1.42) Positive attitude towards COVID-19 Vaccine (6.1; 3.39, 10.91) Previously infected by COVID-19 (4.07; 2.02, 8.21) | 75%              |
| Ahmed, Kanfe et al 2021 | Ethiopia    | Health worker | 409         | 53.1                            | Knowledge about COVID-19 Vaccine (3.02; 1.8, 5.1) Positive attitude towards COVID-19 Vaccine (7.72; 4.02, 14.8) Previously infected by COVID-19 (2.48; 1.43, 4.32) Being male (1.52; 0.89, 2.59) | 87.5%            |
| Angelo, Alemayehu et al 2021 | Ethiopia  | Health worker | 405         | 48.4                            | Knowledge about COVID-19 Vaccine (6.9; 3.9, 14.8) Positive attitude towards COVID-19 Vaccine (7.72; 4.02, 14.8) Previously infected by COVID-19 (2.48; 1.43, 4.32) Being male (1.52; 0.89, 2.59) | 87.5%            |
| Belsti, Gela et al 2021 | Ethiopia    | Population    | 1184        | 31.4                            | Attending above 20 school (4.87; 3.15, 7.53) Living in Urban (1.06; 0.69, 1.62) | 87.5%            |
| Beihun, Walle et al 2021 | Ethiopia   | Patients      | 416         | 59.4                            | Knowledge about COVID-19 Vaccine (6.9; 3.9, 14.8) Positive attitude towards COVID-19 Vaccine (7.72; 4.02, 14.8) Previously infected by COVID-19 (2.48; 1.43, 4.32) Being male (1.52; 0.89, 2.59) | 87.5%            |
| Carpio, Sarasty et al 2021 | Kenya      | Population    | 1050        | 96                              |                                                                                                        | 87.5%            |
| Dereje, Tesfaye et al 2021 | Ethiopia    | Population    | 409         | 80.9                            | Increasing in age (> 40 years) (2.22; 0.94, 5.21) | 87.5%            |
| Echoru, Ajambo et al 2021 | Uganda     | Population    | 1067        | 53.6                            | Increasing in age (> 40 years) (0.52; 0.31, 0.91) Being male (2.1; 1.56, 2.71) Living in Urban (0.78; 0.61, 1.01) | 87.5%            |
| Guangul, Georgescu et al 2021 | Ethiopia   | Health worker | 668         | 72.2                            | Increasing in age (> 40 years) (1.97; 0.2, 19.44) Previously infected by COVID-19 (1.27; 0.65, 2.49) | 87.5%            |
| Handebo, Wolde et al 2021 | Ethiopia    | Teacher       | 301         | 54.8                            | Attending above 20 school (0.8; 0.15, 0.55) Knowledge about COVID-19 Vaccine (1.03; 0.93, 1.13) | 75%              |
| Kanyike, Olum et al 2021 | Uganda      | students      | 600         | 37.3                            | Being male (1.9; 1.3, 2.9) | 75%              |
| Kivuva 2021          | Kenya        | students      | 659         | 51.3                            |                                                                                                        | 75%              |
| Mesele 2021          | Ethiopia      | Population    | 415         | 45.5                            | Attending above 20 school (3.1; 1.7, 5.8) Previously infected by COVID-19 (1.95; 0.63, 6.04) Being male (2.14; 1.29, 3.56) | 75%              |
| Mohamoud, Ali et al 2021 | Somalia    | Population    | 4543        | 76.8                            | Attending above 20 school (2.83; 1.5, 4.2) Knowledge about COVID-19 Vaccine (2.6; 1.8, 3.5) Positive attitude towards COVID-19 Vaccine (1.82; 0.71, 3.64) Living in Urban (2.5; 1.6, 3.9) | 87.5%            |
| Mose 2021            | Ethiopia      | Population    | 630         | 61                              | Attending above 20 school (1.3; 0.87, 1.92) | 87.5%            |
| Orangi, Pinchoff et al 2021 | Kenya     | Population    | 4136        | 63.5                            | Attending above 20 school (1.3; 0.87, 1.92) | 87.5%            |
association, such as having strong, weak, significant and non-significant associations.

These studies have shown inconsistent findings, which did not show the overall level of COVID-19 vaccine acceptance rate and the factors that were significantly associated with it. These were not convenient for policymakers, programmers, decision-makers, planners, and other stakeholders to recognize current vaccination status and design appropriate intervention strategies to improve COVID-19 vaccine acceptance. As to our knowledge, there is no prior systematic review and meta-analysis which shows the pooled prevalence and effect sizes related to level and determinants of COVID-19 vaccine acceptance in East Africa. Therefore, this review aimed to report the estimated pooled prevalence of acceptance rate of COVID-19 vaccine and identification of characteristics associated with COVID-19 vaccine acceptance in East Africa.

**Methods**

**Research Questions**

What is the level of COVID-19 vaccine acceptance in East Africa?

What are the determinants of COVID-19 vaccine acceptance in East Africa?

**Protocol Approval and Registration**

This review has been registered with the International Prospective Register of Systematic Reviews https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021288804; registration number CRD42021288804).

**Study Setting**

This systematic review and meta-analysis included only studies conducted in East Africa.

**Data Source and Search Strategy**

PubMed, Global Health, and Google Scholar were used to retrieve articles. The searching of the published articles was done by using keywords such as; “willingness,” “acceptance,” “hesitancy,” “Intention,” “COVID-19,” “SARS-CoV-2,” “vaccine,” and “Africa.” To combine these keywords; Boolean operators “AND” and “OR” were used. (Supplementary file Table 1).

**Eligibility Criteria**

The CoCoPop (condition, context, and population) and the PEO (population, exposure of interest, and outcome or response approach), respectively, were used to determine studies to be included. All papers that do not full fill these approaches were classified as irrelevant. All included studies were used a cross-sectional study design and have reported the acceptance

| Author, year | Country | Sample size | Study setting | COVID-19 Vaccine acceptance (%) | Associated factors reported (OR; 95% CI) | Quality Score (%) |
|--------------|---------|-------------|---------------|---------------------------------|------------------------------------------|-------------------|
| Ours. Change et al 2021 | Kenya | 665 | Population | 42 | Increasing in age (> 40 years) (1.03; 0.76, 1.39) | 75% |
| Oyebade 2021 | Ethiopia | 2178 | Population | 77.4 | Being male (0.91; 0.77, 1.08) | 75% |
| Situ, Wolde et al 2021 | Ethiopia | 301 | Teacher | 40.8 | Knowledge about COVID-19 Vaccine (0.94; 0.46, 1.9) | 87.5% |
| Taye, Amogne et al 2021 | Ethiopia | 423 | Students | 69.3 | Attending above 2 school (2.23; 1.7, 6.4) | 87.5% |
| Zewude and Bechew 2021 | Ethiopia | 232 | Health worker | 61.6 | Positive attitude towards COVID-19 Vaccine (2.83; 1.83, 4.3) | 75% |
| Zewude and Habekgsa 2021 | Ethiopia | 319 | Population | 46.1 | Knowledge about COVID-19 Vaccine (2.4; 1.57, 3.77) | 75% |
of the COVID-19 vaccine and its determinants in the general population. All papers published in the English language up to February 28, 2022 were included in this systematic review and meta-analysis. The quality of the article was assessed by using of JBI critical appraisal tool, and all articles were passed the quality assessment (Supplementary file Table 2).

**Outcome Measurement**

In this systematic review and meta-analysis, the COVID-19 vaccine acceptance rate was measured as the primary outcome. A dichotomized "Yes" and "No" question was used to determine the prevalence of COVID-19 vaccination acceptance. The effect size (odds ratio) from the included study was used to analyze the factors of COVID-19 vaccination acceptance.

**Data Extraction**

All studies obtained from searching results of all databases were exported to Endnote version 20.2 software and transported into Covidence systematic review manager online web-based software. Then duplicates were removed. Finally, all articles were evaluated to see if they satisfied the inclusion criteria using title and abstract, as well as a full-text review. Then, those studies that met the inclusion criteria were exported to a Microsoft Excel spreadsheet for data extraction.

Structured data abstraction sheet was constructed and pre-tested. For each study that met our eligibility criteria, two authors (AA and AD) independently extract the title, name of authors, year of publication, country, study design, study population, sample size, mean age, the proportion of Vaccine acceptance, and effect sizes with 95% confidence intervals.

**Quality Assessment**

In this systematic review and metanalysis, all included articles were cross-sectional studies. The risk of bias (quality of research) was assessed by the same authors (AA and AD) independently using the JBI (Joanna Briggs Institute) critical assessment checklist for cross-sectional studies. This review comprised high-quality papers with a quality score of 75% or higher, and disagreements were handled by consensus.41

![Figure 2. Forest plot of pooled prevalence of COVID-19 vaccine acceptance among general population in East Africa, 2022.](image-url)
**Data Synthesis and Reporting**

The overall, process and result of this systematic review and meta-analysis were written and reported according to the PRISMA flowchart diagram and Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) updated guideline, respectively. The PRISMA checklist has been completed (Supplementary file Table 3).

**Statistical Analysis**

STATA version 17 software was used for analysis. The proportion of COVID-19 vaccine acceptance, odd ratio, and confidence interval (CI) of determinants was pooled using a random-effect model and weighting method using a forest plot. Heterogeneity was assessed or determined by using $I^2$ statistics. The funnel plot was visually inspected for publication bias and Egger’s test statistics with a p-value <0.05 are considered as significant evidence of publication bias. Trim-and-fill analysis was used to identify the risk of bias due to missing studies in the results. In order to find a possible source of heterogeneity, subgroup analysis, and sensitivity analyses were used.

**Result**

A comprehensive search strategy on different databases, including PubMed, Global Health, and Google Scholar, were used to retrieve the published articles. A total of 3206 articles were identified. From these, 36 articles were excluded because of duplication. From 3170 articles left, 1311 articles were excluded by the titles and abstracts were excluded by the titles and abstracts due to their

---

**Figure 3.** Forest plot shows subgroup analysis of pooled prevalence of COVID-19 vaccine acceptance among general population in East Africa by country, 2022.
After a full-text review of 54 articles, 29 of them were excluded with reason. Finally, the eligibility of 25 publications was reviewed, and they were all included in this review (Figure 1).

**Characteristics of the Included Studies**

A total of 25 published cross-sectional studies were included in this systematic review and meta-analysis with a total sample size of 33,044. Of these, the largest sample size was 17,212 from Kenya, while the smallest sample size was 1667 from Uganda. The highest and lowest prevalence of COVID-19 vaccine acceptance rates were 76.8% from Somalia and 47.7% from Uganda, respectively (Table 1).

**Prevalence of COVID-19 Vaccine Acceptance Rate in East Africa**

Overall, a meta-analysis of the random effect model estimated that the pooled prevalence of the Covid-19 vaccine acceptance rate in east Africa was 60.2% (95%CI: 52.8-67.3) and the level of heterogeneity was ($I^2 = 99.4\%$, $P = 0.00$) (Figure 2).

**Subgroup analysis.** Subgroup analysis by country showed, the pooled prevalence of COVID-19 vaccine acceptance in Kenya was 68.5% (95% CI: 53.3-81.8, $I^2 = 99.7\%$, $P = 0.0$), in Ethiopia were 58.3% (95% CI: 46.7-69.5, $I^2 = 99.2\%$, $P = 0.0$) and in Uganda were 47.7% (95% CI: 45.3-50.1; $I^2 = 0.0\%$, $P = 0.000$) (Figure 3). Similarly, subgroup analysis was done using study participants, the pooled prevalence of COVID-19 vaccine acceptance among general population (Figure 4).
among population (community) was 64.6% (95%CI: 54.9-73.7, $I^2 = 99.6\%$, $p = 0.0$), among patients were 56.9% (95%CI: 53.6-60.3; $I^2 = 0.0\%$, $p = 0.0$), among Health worker were 56.4% (95%CI: 45.4-67.1; $I^2 = 96.2\%$, $p = 0.0$), among teacher were 47.8% (95%CI: 43.8-51.8; $I^2 = 0.0\%$, $p = 0.0$), and 50.7% among students (95%CI: 47.6-53.7; $I^2 = 0.0\%$, $p = 0.0$) (Figure 4).

**Figure 5.** Bubble plot show the association of a sample size of the study and COVID-19 vaccine acceptance based on meta-regression.

**Figure 6.** Funnel plot shows publication bias with imputation of missing studies of pooled prevalence of COVID-19 vaccine acceptance among general population in east Africa, 2022.
Heterogeneity test. In this meta-analysis the test statistics of heterogeneity test of $I^2$ indicated that there is significant high heterogeneity, so we used a random-effects model to adjust for the observed variability and subgroup analysis was used to examine the occurrence and the likely source of heterogeneity. However, the level of heterogeneity was high after subgroup analysis (Figure 3, Figure 4). In addition, we have used a meta-regression model for further investigation of sources of heterogeneity by using sample size as a covariate. Meta-regression has many aspects or qualities and better method than subgroup analysis for investigating heterogeneity.\textsuperscript{57} The result of the meta-regression analysis showed that the covariate or the variability in a sample size of the primary studies were statistically significant for the presence of heterogeneity (Figure 5, Supplementary file: Table 4).

Publication bias. The publication bias was assessed by using a visual impression of the funnel plot and Egger$'$s test statistics. Egger$'$s test statistics ($P = 0.003$) showed there were statistically significant small-study effects, this suggests that there was publication bias. Also, the unequal distribution of the included articles in the funnel plot shows that this meta-analysis has signs of publication bias for this meta-analysis of pooled prevalence of COVID-19 vaccine acceptance (Figure 6, Supplementary file: Table 5).

Sensitivity analysis. The sensitivity analysis indicated that there was no single study that influenced the overall COVID-19 vaccine acceptance among the general population in East Africa (Figure 7).

Determinant of COVID-19 Vaccine Acceptance in East Africa

In this meta-analysis, the determinant factors of COVID-19 vaccine acceptance were reported using pooled effect sizes with 95%CI. Eighteen researchs reported the determinants of COVID-19 vaccine acceptability. The determinants reported by these studies include, attending above secondary school,\textsuperscript{14,15,20,22,25,26,29,32,34,36,38} having good knowledge about COVID-19 Vaccine,\textsuperscript{14,16,17,22,25,29,36,38} having positive attitude toward COVID-19 vaccine,\textsuperscript{14,17,25,31,37} previously infected by COVID-19,\textsuperscript{14,17,21,31,34} and being male\textsuperscript{17,20,22,26,33,34,36} were found to have significant association with COVID-19 vaccine acceptance (Table 2).

Discussion

This is the first systematic review and meta-analysis that tried to investigate the level and determinants of COVID-19 vaccine acceptance among the general population in East Africa. Researchers, health care policymakers and implementers, government, communities, and healthcare professionals will all benefit from this knowledge. The estimated pooled prevalence of COVID-19 vaccination acceptance rate among the general population in East Africa

![Figure 7. The sensitivity analysis result of 25 included studies conducted on COVID-19 vaccine acceptance among general population in East Africa, 2022.](image-url)
| Determinants of COVID-19 Vaccine Acceptance | First Author | OR (95%CI) | POR (95%CI) | Heterogeneity test |
|-------------------------------------------|-------------|------------|-------------|-------------------|
| Attending above second school              | Abebe, Shitu et al 2021 | 2.59 (1.52, 4.39) | 2.01 (1.37, 2.96) | 77.5% 0.000 |
|                                           | Admasu 2021 | 3.01 (1.48, 6.89) |             |                   |
|                                           | Aemro, Amare et al 2021 | 1.2 (0.7, 2.3) |             |                   |
|                                           | Belsti, Gela et al 2021 | 4.87 (3.15, 7.53) |             |                   |
|                                           | Echoru, Ajambo et al 2021 | 2.8 (1.18, 6.66) |             |                   |
|                                           | Handebo, Wolde et al 2021 | 0.8 (0.15, 0.55) |             |                   |
|                                           | Mesele 2021 | 3.1 (1.7, 5.8) |             |                   |
|                                           | Mose 2021 | 2.83 (1.5, 4.2) |             |                   |
|                                           | Orangi, Pinchoff et al 2021 | 1.3 (0.87, 1.92) |             |                   |
|                                           | Shitu, Wolde et al 2021 | 0.68 (0.31, 1.51) |             |                   |
|                                           | Taye, Amogne et al 2021 | 2.63 (0.84, 8.18) |             |                   |
| Increasing in age (> 40 years)             | Abebe, Shitu et al 2021 | 2.36 (1.1, 5.4) | 1.2 (0.72, 2.01) | 63.7% 0.017 |
|                                           | Admasu 2021 | 1.13 (0.33, 3.91) |             |                   |
|                                           | Dereje, Tesfaye et al 2021 | 2.22 (0.94, 5.21) |             |                   |
|                                           | Echoru, Ajambo et al 2021 | 0.52 (0.31, 0.91) |             |                   |
|                                           | Guangul, Georgescu et al 2021 | 1.97 (0.2, 19.44) |             |                   |
|                                           | Orangi, Pinchoff et al 2021 | 1.03 (0.76, 1.39) |             |                   |
| Having good knowledge about the COVID-19 Vaccine | Abebe, Shitu et al 2021 | 2.59 (1.16, 4.02) | 2.11 (1.56, 2.85) | 92.8% 0.000 |
|                                           | Admasu 2021 | 6.9 (3.1, 15.2) |             |                   |
|                                           | Ahmed, Kanfe et al 2021 | 1.31 (1.23, 1.42) |             |                   |
|                                           | Berhun, Walle et al 2021 | 6.9 (3.9, 14.8) |             |                   |
|                                           | Handebo, Wolde et al 2021 | 1.03 (0.93, 1.13) |             |                   |
|                                           | Mose 2021 | 2.6 (1.8, 3.5) |             |                   |
|                                           | Shitu, Wolde et al 2021 | 0.94 (0.46, 1.9) |             |                   |
|                                           | Taye, Amogne et al 2021 | 2.4 (1.57, 3.77) |             |                   |
| Having a positive attitude toward the COVID-19 Vaccine | Admasu 2021 | 3.05 (1.03, 4.05) | 3.82 (2.35, 6.19) | 67.8% 0.015 |
|                                           | Angelo, Alemaryahu et al 2021 | 6.1 (3.39, 10.91) |             |                   |
|                                           | Berhun, Walle et al 2021 | 7.72 (4.02, 14.8) |             |                   |
|                                           | Mose 2021 | 1.82 (0.71, 3.64) |             |                   |
|                                           | Zewude and Habtiegirgis 2021 | 2.83 (1.83, 4.3) |             |                   |
| Previously infected by COVID-19            | Admasu 2021 | 6 (2.5, 11.8) | 2.74 (1.6, 4.68) | 62.4% 0.031 |
|                                           | Angelo, Alemaryahu et al 2021 | 4.07 (2.02, 8.21) |             |                   |
|                                           | Berhun, Walle et al 2021 | 2.48 (1.43, 4.32) |             |                   |
|                                           | Guangul, Georgescu et al 2021 | 1.27 (0.65, 2.49) |             |                   |
|                                           | Mesele 2021 | 1.95 (0.63, 6.04) |             |                   |
| Being Male                                | Berhun, Walle et al 2021 | 1.52 (0.89, 2.59) | 1.78 (1.15, 2.75) | 88.6% 0.000 |
|                                           | Echoru, Ajambo et al 2021 | 2.1 (1.56, 2.71) |             |                   |
|                                           | Kanyike, Olum et al 2021 | 1.9 (1.3, 2.9) |             |                   |
|                                           | Mesele 2021 | 2.14 (1.29, 3.56) |             |                   |
|                                           | Orangi, Pinchoff et al 2021 | 0.91 (0.77, 1.08) |             |                   |
|                                           | Shitu, Wolde et al 2021 | 3.23 (1.7, 6.14) |             |                   |

(continued)
was 60.2%, according to this systematic review and meta-analysis of 25 articles. In addition, several determinant factors were significantly associated with the level of COVID-19 vaccine acceptance. Among these, attending the above secondary school, having a positive attitude toward the COVID-19 vaccine, and people previously infected by COVID-19 were found to have a strong association with COVID-19 vaccine acceptance.

This finding was consistent with the study conducted in South Carolina (60.6%), China (60.4%), Sixty-three percent (63%) in China, United States (63.7%), Saudi Arabia (64.72%), Japan (65.7%), United States (66.0%). However, this result was higher than previous research conducted in Jordan (36.8%), Jordan (37.4%), Kuwait (53.1%), Palestine (40%), Malaysia (48.2%), England (55.8%), Greece (57.7%), and Saudi Arabia (48%). But it was lower than studies conducted in Turkey (84.6%), Australia (80%), UK (86%), Israel (85%), Bangladesh (74.6%), Iran (64.2%), Italy (86.1%), France (77.6%), Vietnam (76.10%), Pakistan (70.25%), and eighty percent (80%) in the Caribbean and South America. The observed discrepancy could be explained by changes in the study population’s sociodemographic parameters as well as the study participants’ level of awareness about the COVID-19 vaccine.

In this meta-analysis, having a positive attitude toward COVID-19 Vaccine was significantly associated with COVID-19 vaccine acceptance, this is similar to studies conducted in Asia had shown that a positive attitude toward vaccination is associated with vaccine acceptance. Attending above second school was significantly associated with COVID-19 vaccine acceptance. This finding was in line with a recent study that found that persons with more education receive the COVID-19 vaccine. Individuals with a higher levels of education recorded as having a substantially higher level of knowledge about COVID-19 vaccine acceptance. Furthermore, as a result of enhanced access to more media sources and a growing interest in life activities that may influence them, more informed people are likely to be more aware of and concerned about their health and well-being.

In this review, Being Male was significantly associated with COVID-19 vaccine acceptance, this was consistent with previous studies, that had shown, men are more likely to accept the COVID-19 vaccine. Previously infected by COVID-19, having good knowledge about COVID-19 Vaccines, were significantly associated with COVID-19 vaccine acceptance in east Africa. This is most likely owing to improved access to high-quality information, such as through the media, and/or the fact that these people tend to live in areas where the virus is more widespread.

**Strength and Limitation of the Study**

The overall review process was conducted using the Covidence review manager web-based software. The bias may be present because the search and inclusion criteria of the study were...
those studies conducted just in the English language. There is significant publication bias. In addition, there is a lack of data in most countries may make it a problem to generalize the findings. Therefore, in those countries with a lack of data, we suggest more studies be conducted in the future.

Conclusion

Overall, the COVID-19 vaccination acceptance rate was a little better than average, but it could be improved. The findings of this study revealed that having a positive attitude toward the COVID-19 Vaccine has the largest odd ratio, followed by having been previously infected with COVID-19, having good information about the COVID-19 Vaccine, attending above secondary school, and being male. The findings of this study could help the government figure out the best way to carry out COVID-19 mass vaccination campaigns. In addition, the government’s, healthcare professionals, and stakeholders’ commitment to COVID-19 preventive activities could have a significant impact on the vaccine’s acceptability.

Acknowledgment

First of all, we would like to express our thanks to the almighty God. We would also like to extend our gratitude to Harar Health Science College for providing funds to conduct this study. Finally, we thank Mr Merga Hirko, Dr Abebe Desalegn, and Mrs. Ikram Mohammed for editing the language and grammatical flow.

Author Contribution

All authors contributed significant work to this review.

Data Availability

At any time, the corresponding author provides an additional resource on request.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Harar Health Science College.

ORCID iDs

Astawus Alemayehu https://orcid.org/0000-0003-1384-7123
Mohammed Yusuf https://orcid.org/0000-0002-1091-9235

Supplemental material

Supplemental material for this article is available online.

References

1. WHO. WHO Director-General’s opening remarks at the media briefing on COVID-19—11 March 2020. Updated 11 March 2020. Accessed February 1, 2022. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020.
2. PAHO. WHO declares Public Health Emergency on novel coronavirus. Updated 30 Jan 2020. Accessed February 1, 2022. https://www.paho.org/en/news/30-1-2020-who-declares-public-health-emergency-novel-coronavirus.
3. WHO. WHO Coronavirus (COVID-19) Dashboard Accessed January 10, 2022. https://covid19.who.int/.
4. WHO. WHO Coronavirus (COVID-19) Dashboard. Accessed January 10, 2022. https://covid19.who.int/region/afro/country/et.
5. Baye K. COVID-19 prevention measures in Ethiopia: Current realities and prospects. International Food Policy Research Institute (IFPRI). 2020;ESSP Working Paper 141.
6. Emre A. Steps taken by countries in fighting COVID-19 pandemic. Anadolu Agency. https://www.aa.com.tr/en/health/steps-taken-by-countries-in-fighting-covid-19-pandemic/1812009#.
7. Zikargae MH. COVID-19 in Ethiopia: assessment of how the Ethiopian government has executed administrative actions and managed risk communications and community engagement. Risk Manag Healthc Policy. 2020;13:2803–2810. doi:10.2147/RMHP.S278234
8. Güner R, Hasanoğlu I, Aktaş F. COVID-19: prevention and control measures in community. Turk J Med Sci. 2020;50(SI-1):571–577. doi:10.3906/sag-2004-146
9. Kata A. A postmodern pandora’s box: anti-vaccination misinformation on the internet. Vaccine. Feb 17 2010;28(7):1709–1716. doi:10.1016/j.vaccine.2009.12.022
10. Hornsey MJ, Harris EA, Fielding KS. The psychological roots of anti-vaccination attitudes: a 24-nation investigation. Health Psychol. Apr 2018;37(4):307–315. doi:10.1037/hea0000586
11. Jolley D, Douglas KM. Prevention is better than cure: addressing anti-vaccine conspiracy theories. J Appl Soc Psychol. 2017;47(8):459–469.
12. Waszak PM, Kasprzycka-Waszak W, Kubanek A. The spread of medical fake news in social media—the pilot quantitative study. Health Policy Technol. 2018;7(2):115–118.
13. Islam MS, Kamal AM, Kabir A, et al. COVID-19 vaccine rumors and conspiracy theories: the need for cognitive inoculation against misinformation to improve vaccine adherence. PloS one. 2021;16(5):e0251605. doi:10.1371/journal.pone.0251605
14. Admasu FT. Knowledge and proportion of COVID-19 vaccination and associated factors among cancer patients attending public hospitals of Addis Ababa, Ethiopia, 2021: a multicenter study. Infection Drug Resist. 2021;14:4865–4876.
15. Aemro A, Amare NS, Shetie B, Chekol B, Wassie M. Determinants of COVID-19 vaccine hesitancy among health care workers in Amhara region referral hospitals, Northwest Ethiopia: a cross-sectional study. Epidemiology & Infection. 2021;149:e225.
16. Ahmed MH, Kanfe SG, Jarso MH. Intention to receive vaccine against COVID-19 and associated factors among health professionals working at public hospitals in resource limited settings. PloS one. 2021;16(7):e0254391.
17. Berihun G, Walle Z, Berhanu L, Teshome D. Acceptance of COVID-19 vaccine and determinant factors among patients with chronic disease visiting dessie comprehensive specialized
hospital, Northeastern Ethiopia. Patient Prefer Adherence. 2021;15:1795–1805.

18. Carpio CE, Sarasty O, Hudson D, Macharia A, Shibia M. The demand for a COVID-19 vaccine in Kenya. Hum Vacc Immunother. 2021;17(10):3463–3471.

19. Dereje N, Tesfaye A, Tamene B, et al. COVID-19 Vaccine hesitancy in Addis Ababa, Ethiopia: a mixed-methods study. BMJ Open 2022;12(5):e052432.

20. Echoru I, Ajambo PD, Keirania E, Bukanya EEM. Sociodemographic factors associated with acceptance of COVID-19 vaccine and clinical trials in Uganda: a cross-sectional study in western Uganda. BMC public Health. 2021;21(1):1106. doi:10.1186/s12889-021-11197-7

21. Guangul BA, Georgescu G, Osman M, et al. Healthcare workers attitude towards SARS-COVID-2 vaccine, Ethiopia. Global J Infect Dis Clin Res. 2021;7(1):043–048.

22. Handebo S, Wolde M, Shitu K, Kassie A. Determinant of intention to receive COVID-19 vaccine among school teachers in Gondar City, Northwest Ethiopia. PloS one. 2021;16(6):e0253499.

23. Kivuva EW. ASSESSING THE RELATION BETWEEN COVID-19 PERCEPTION AND ACCEPTANCE OF THE COVID-19 VACCINE IN KENYA. 2021.

24. Mohamoud SA, Ali MA, Muse AM, Bile AS, Mohmud AJ. COVID-19 Vaccine Rollout in Somalia: Experiences and Challenges in Fragile Context. 2021;

25. Mose A. Willingness to receive COVID-19 vaccine and its determinant factors among lactating mothers in Ethiopia: a cross-sectional study. Infect Drug Resist. 2021;14:4249–4259.

26. Orangi S, Pinchoff J, Mwanga D, et al. Assessing the level and determinants of COVID-19 vaccine confidence in Kenya. Vaccines. 2021;9(8):936.

27. Oyekale AS. Willingness to take COVID-19 vaccines in Ethiopia: an instrumental variable probit approach. Int J Environ Res Public Health. 2021;18(17):8892.

28. Oyekale AS. Compliance indicators of COVID-19 prevention and vaccines hesitancy in Kenya: a random-effects endogenous probit model. Vaccines (Basel). 2021;9(11):1359.

29. Taye BT, Amogne FK, Demisse TL, et al. Coronavirus disease 2019 vaccine acceptance and perceived barriers among university students in northeast Ethiopia: a cross-sectional study. Clin Epidemiol Glob Health. 2021;12:100848.

30. Zewude B, Belachew A. Intention to receive the second round of COVID-19 vaccine among healthcare workers in Eastern Ethiopia. Infect Drug Resist. 2021;14:3071–3082.

31. Angelo AT, Alemayehu DS, Dachew AM. Health care workers intention to accept COVID-19 vaccine and associated factors in southwestern Ethiopia, 2021. PloS one. 2021;16(9):e0257109.

32. Belsti Y, Gela YY, Akalu Y, et al. Willingness of Ethiopian population to receive COVID-19 vaccine. J Multidiscip Healthc. 2021;14:1233–1243.

33. Kanyike AM, Olum R, Kajjimu J, et al. Acceptance of the coronavirus disease-2019 vaccine among medical students in Uganda. Trop Med Health. 2021;49(1):37. doi:10.1186/s41182-021-00331-1

34. Mesele M. COVID-19 vaccination acceptance and its associated factors in sodo town, wolaita zone, Southern Ethiopia: cross-sectional study. Infect Drug Resist. 2021;14:2361–2367.

35. Osar JO, Chengo R, Muinga E, Kembbi J, Sidibe M, Rarieya M. Determinants of COVID-19 Vaccine Behaviour Intentions Among The Youth In Kenya: A Vaccine Pre-Introduction Study. 2021.

36. Shitu K, Wolde M, Handebo S, Kassie A. Acceptance and willingness to pay for COVID-19 vaccine among school teachers in Gondar City, Northwest Ethiopia. Trop Med Health. 2021;49(1):1–12.

37. Zewude B, Habtegiorgis T. Willingness to take COVID-19 vaccine among people most at risk of exposure in Southern Ethiopia. Pragmatic Observational Res. 2021;12:37–47.

38. Abebe H, Shitu S, Mose A. Understanding of COVID-19 vaccine knowledge, attitude, acceptance, and determinates of COVID-19 vaccine acceptance among adult population in Ethiopia. Infect Drug Resist. 2021;14:2015–2025.

39. Moola S, Munn Z, Sears K, et al. Conducting systematic reviews of association (etiology): the Joanna Briggs institute’s approach. Int J Evid Based Healthc. Sep 2015;13(3):163–169. doi:10.1097/exeb.0000000000000664

40. Munn Z, Moola S, Lisy K, Ritano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int J Evid Based Healthc. Sep 2015;13(3):147–153. doi:10.1097/exeb.000000000000054

41. manual: JBUHr. edition The Systematic Review of Prevalence and Incidence Data. The University of Adelaide: The Joanna Briggs Institute, 2014, 2014.

42. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J. Mar 29 2021;372:n71. doi:10.1136/bmj.n71

43. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558. doi:10.1002/sim.1186

44. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J. 2003;327(7414):557–560. doi:10.1136/bmj.327.7414.557

45. Huedo-Medina TB, Sánchez-Meca J, Marin-Martínez F, Botella J. Assessing heterogeneity in meta-analysis: q statistic or I2 index? Psychol Methods. Jun 2006;11(2):193–206. doi:10.1037/1082-998x.11.2.193

46. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J. 1997;315(7109):629–634. doi:10.1136/bmj.315.7109.629

47. Hardy RJ, Thompson SG. Detecting and describing heterogeneity in meta-analysis. Stat Med. 1998;17(8):841–856.

48. Tam CC, Qiao S, Li X. Factors associated with decision making on COVID-19 vaccine acceptance among college students in south Carolina. Psychol Health Med. 2022;27(1):150–161. doi:10.1080/13524558.2020.2043543

49. Gan L, Chen Y, Hu P, et al. Willingness to receive SARS-CoV-2 vaccination and associated factors among Chinese adults: a cross-sectional survey. Int J Environ Res Public Health. 2021;18(4):1993. doi:10.3390/ijerph18041993

50. Kwok KO, Li K-K, Wei W, Tang A, Wong SYS, Lee SS. Editor choice: influenza vaccine uptake, COVID-19 vaccination intention and vaccine hesitancy among nurses: a survey. Int J Nurs Stud. 2021;114:103854–103854. doi:10.1016/j.in urstu.2020.103854

51. Kuter BJ, Browne S, Momplaisir FM, et al. Perspectives on the receipt of a COVID-19 vaccine: a survey among employees in two
large hospitals in Philadelphia. *Vaccine*. 2021;39(12):1693–1700. doi:10.1016/j.vaccine.2021.02.029

52. Al-Mohaithef M, Padhi BK. Determinants of COVID-19 vaccine acceptance in Saudi Arabia: a web-based national survey. *J Multidiscip Healthc*. 2020;13:1657–1663. doi:10.2147/jmjh.S276771

53. Yoda T, Katsuyama H. Willingness to receive COVID-19 vaccination in Japan. *Vaccines (Basel)*. Jan 14 2021;9(1):48. doi:10.3390/vaccines9010048

54. Ehde DM, Roberts MK, Herring TE, Alschuler KN. Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States. *Mult Scler Relat Disord*. Apr 21 2021;49:102788. doi:10.1016/j.msard.2021.102788

55. Al-Qerem WA, Jarab AS. COVID-19 Vaccination acceptance and its associated factors among a middle eastern population. *Front Public Health*. 2021;9:632914. doi:10.3389/fpubh.2021.632914

56. El-Elimat T, AbuAlSamen MM, Almomanabi BA, Al-Sawalha NA, Alali FQ. Acceptance and attitudes toward COVID-19 vaccines: a cross-sectional study from Jordan. *PloS One*. 2021;16(4):e0250555. doi:10.1371/journal.pone.0250555

57. Alqudeimat Y, Alenezi D, AlHajri B, et al. Acceptance of a COVID-19 vaccine and its related determinants among the general adult population in Kuwait. *Med Prin Pract*. 2021;30(3):262–271.

58. Rabi R, Maraqa B, Nazzal Z, Zink T. Factors affecting nurses’ intention to accept the COVID-19 vaccine: a cross-sectional study. *Public Health Nurs*. 2021;38(5):781–788.

59. Wong LP, Alias H, Wong P-F, Lee HY, AbuBakar S. The use of the health belief model to assess predictors of intent to receive the COVID-19 vaccine and willingness to pay. *Hum Vaccin Immunother*. 2020;16(9):2204–2214.

60. Bell S, Clarke R, Mounier-Jack S, Walker JL, Paterson P. Parents’ and guardians’ views on the acceptability of a future COVID-19 vaccine: a multi-methods study in England. *Vaccine*. Nov 17 2020;38(49):7789–7798. doi:10.1016/j.vaccine.2020.10.027

61. Kourlaba G, Kourkouni E, Maistrelli S, et al. Willingness of Greek general population to get a COVID-19 vaccine. *Glob Health Res Policy*. Jan 29 2021;6(1):3. doi:10.1186/s41256-021-00188-1

62. Alfageeh EL, Alshareef N, Angawi K, Alhazmi F, Chiware GC. Acceptability of a COVID-19 vaccine among the Saudi population. *Vaccines (Basel)*. 2021;9(3):226. doi:10.3390/vaccines9030226

63. Kaplan AK, Sahin MK, Paridlar H, Adadan Guvenc I. The willingness to accept the COVID-19 vaccine and affecting factors among healthcare professionals: a cross-sectional study in Turkey. *Int J Clin Pract*. 2021;75(7):e14226. doi:10.1111/iarp.14226

64. Seale H, Heywood AE, Leask J, et al. Examining Australian public perceptions and behaviours towards a future COVID-19 vaccine. *BMC Infect Dis*. Jan 28 2021;21(1):120. doi:10.1186/s12879-021-05833-1

65. Williams L, Gallant AJ, Rasmussen S, et al. Towards intervention development to increase the uptake of COVID-19 vaccination among those at high risk: outlining evidence-based and theoretically informed future intervention content. *Br J Health Psychol*. Nov 2020;25(4):1039–1054. doi:10.1111/bjhp.12468

66. Zigron A, Dror AA, Morozov NG, et al. COVID-19 Vaccine acceptance among dental professionals based on employment Status during the pandemic. *Front Med (Lausanne)*. 2021;8:618403. doi:10.3389/fmed.2021.618403

67. Abedin M, Islam MA, Rahman FN, et al. Willingness to vaccinate against COVID-19 among Bangladeshi adults: understanding the strategies to optimize vaccination coverage. *PloS One*. 2021;16(4):e0250495. doi:10.1371/journal.pone.0250495

68. Askarian M, Fu L, Taghiri MH, et al. Factors affecting COVID-19 vaccination intent among Iranians: COVID-19 vaccination acceptance. 2020.

69. Barelo S, Nania T, Dellafiore F, Graffigna G, Caruso R. ‘Vaccine hesitancy’ among university students in Italy during the COVID-19 pandemic. *Eur J Epidemiol*. Aug 2020;35(8):781–783. doi:10.1007/s10654-020-00670-z

70. Detoc M, Brulé S, Frappe T, Tardy B, Botelho-Nevers E, Gagnex-Brunon A. Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic. *Vaccine*. Oct 21 2020;38(45):7002–7006. doi:10.1016/j.vaccine.2020.09.041

71. Huynh G, Tran TT, Nguyen HTN, Pham LA. COVID-19 vaccination intention among healthcare workers in Vietnam. *Asian Pac J Trop Med*. 2021;14(4):159.

72. Malik A, Malik J, Ishaq U. Acceptance of COVID-19 vaccine in Pakistan among health care workers. *PloS One*. 2021;16(9):e0257237–e0257237. doi:10.1371/journal.pone.0257237

73. Urrunaga-Pastor D, Bendez-Quispe G, Herrera-Añacez P, et al. Cross-sectional analysis of COVID-19 vaccine intention, perceptions and hesitancy across Latin America and the Caribbean. *Travel Med Infect Dis*. May-Jun 2021;41:102059. doi:10.1016/j.tmtd.2021.102059

74. Rajamoorthy Y, Radam A, Taib NM, et al. The relationship between perceptions and self-paid hepatitis B vaccination: a structural equation modeling approach. *PloS One*. 2018;13(12):e0208402. doi:10.1371/journal.pone.0208402

75. Rajamoorthy Y, Radam A, Taib NM, et al. Willingness to pay for hepatitis B vaccination in selangor, Malaysia: a cross-sectional household survey. *PloS One*. 2019;14(4):e0215125. doi:10.1371/journal.pone.0215125

76. Sundaram N, Purohit V, Schaetti C, Kudale A, Joseph S, Weiss MG. Community awareness, use and preference for pandemic influenza vaccines in Pune, India. *Hum Vaccin Immunother*. 2015;11(10):2376–2388. doi:10.1080/21645515.2015.1062956

77. Sherman SM, Smith LE, Sim J, et al. COVID-19 vaccination intention in the UK: results from the COVID-19 vaccination acceptability study (CoVAccS), a nationally representative cross-sectional survey. *Hum Vaccin Immunother*. 2021;17(6):1612–1621. doi:10.1080/21645515.2020.1846397

78. Sallam M, Bababesh D, Eid H, et al. High rates of COVID-19 vaccine hesitancy and its association with conspiracy beliefs: a study in Jordan and Kuwait among other Arab countries. *Vaccines (Basel)*. 2021;9(1):42. doi:10.3390/vaccines9010042

79. Wang K, Wong EL, Ho KF, et al. Change of willingness to accept COVID-19 vaccine and reasons of vaccine hesitancy of working people at different waves of local epidemic in Hong Kong, China: repeated cross-sectional surveys. *Vaccines (Basel)*. 2021;9(1):62. doi:10.3390/vaccines9010062

80. Lazarus JV, Ratzan SC, Palayew A, et al. A global survey of potential acceptance of a COVID-19 vaccine. *Nat Med*. Feb 2021;27(2):225–228. doi:10.1038/s41591-020-1124-9